Summary : HYFTOR™ is the first topical treatment approved by the FDA for facial angiofibroma in individuals with tuberous sclerosis complex (TSC) 6…
@2021 – All Right Reserved. Designed and Developed by Ample eBusiness
Monthly Archives
April 2022
-
-
Summary : The Venus VivaTM will now make its American premiere, having already established itself as a pioneer in the worldwide medical…
-
Global MarketPatent infringementPatents
FMC Corporation Wins Patent Infringement Case Against Udragon for Chlorantraniliprole
by adminby adminSummary : The Hangzhou Intermediate People’s Court in Zhejiang Province, China, awarded FMC a permanent injunction against Hangzhou Udragon Chemical Co., Ltd…
-
Global MarketRegulatoryU.S FDA
Sol-Gel Technologies and Galderma’s EPSOLAY® Scores US FDA Approval
by adminby adminSummary: EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and is patent…
-
Covid DrugsGileadRegulatoryU.S FDA
Gilead’s Veklury Becomes the First FDA-approved COVID-19 Treatment for Infants
by adminby adminSummary : The first treatment for COVID-19 in young children has been approved by the US Food and Drug Administration. In this…
-
Merger / AcquisitionPiramal Group
Piramal Pharma To Acquire Hemmo Pharma For Rs 775 Cr
by adminby adminSummary : Piramal Enterprises said in a regulatory filing on Wednesday that its subsidiary Piramal Pharma Ltd has signed into a deal…
-
Alembic PharmaMerger / Acquisition
Alembic Pharma acquires 100% stake in Aleor Dermaceuticals
by adminby adminSummary : The company has acquired remaining 40 per cent stake from Orbicular Pharmaceutical Technologies, to have 100 per cent holding in…
-
CompaniesIndiaMerger / AcquisitionNovartis
Dr. Reddy’s will Pay Rs 463 Crore for Novartis’ Cardiovascular Drug Cidmus (Valsartan +Sacubitril)
by adminby adminSummary Dr Reddy’s Laboratories, an Indian generic pharmaceutical company, has agreed to pay $61 million to Novartis AG for the cardiovascular brand…
-
Summary : AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement…
-
RegulatoryU.S FDA
Alymsys® (Bevacizumab-maly), a Biosimilar of Bevacizumab developed by mAbxience, has been Approved by the FDA.
by adminby adminSummary : ALYMSYS® was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization…
Newer Posts